Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-α antagonists

Joint Bone Spine

Volumn 73, Issue 3, 2006, Pages 270-277

  Mulleman, Denis ^a,b   Mammou, Saloua ^b   Griffoul, Isabelle ^b   Watier, Hervé ^a   Goupille, Philippe ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

Disk related sciatica; TNF antagonists; Tumor necrosis factor alpha

Indexed keywords

ETANERCEPT; HEPARIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; HUMAN; ISCHIALGIA; LOW BACK PAIN; NONHUMAN; NUCLEUS PULPOSUS; PATHOGENESIS; PATHOPHYSIOLOGY; SCHWANN CELL; SHORT SURVEY;

ANIMALS; ANTIBODIES, MONOCLONAL; DOXYCYCLINE; HUMANS; LOW BACK PAIN; NEURALGIA; PENTOXIFYLLINE; RANDOMIZED CONTROLLED TRIALS; RATS; SCIATICA; SPINAL NERVE ROOTS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646033133     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.03.004     Document Type: Short Survey

References (88)

1. Mixter W.J., and Barr J.S. Rupture of the intervertebral disc with involvement of the spinal canal. N. Engl. J. Med. 211 (1934) 210-215
2. Olmarker K., and Myers R.R. Pathogenesis of sciatic pain: role of herniated nucleus pulposus and deformation of spinal nerve root and dorsal root ganglion. Pain 78 (1998) 99-105
3. Olmarker K., Rydevik B., and Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. Spine 18 (1993) 1425-1432
4. Olmarker K., Brisby H., Yabuki S., Nordborg C., and Rydevik B. The effects of normal, frozen, and hyaluronidase-digested nucleus pulposus on nerve root structure and function. Spine 22 (1997) 471-475
5. Kayama S., Olmarker K., Larsson K., Sjogren-Jansson E., Lindahl A., and Rydevik B. Cultured, autologous nucleus pulposus cells induce functional changes in spinal nerve roots. Spine 23 (1998) 2155-2158
6. Olmarker K., and Larsson K. Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury. Spine 23 (1998) 2538-2544
7. Mulleman D., Mammou S., Griffoul I., Watier H., and Goupille P. Pathophysiology of disk-related sciatica. I-evidence supporting a chemical component?. Joint Bone Spine 72 (2005) (this issue)
8. Wendling D. Anti-TNFα therapy in spondyloarthropathy: deciding who to treat. Joint Bone Spine 70 (2003) 401-403
9. Mugnier B. Factors predicting responsiveness to anti-TNFα therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 71 (2004) 91-94
10. Combe B. Switching between anti-TNFα agents: what is the evidence?. Joint Bone Spine 71 (2004) 169-171
11. Berthelot J.M., and Varin S. Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents. Joint Bone Spine 71 (2004) 257-260
12. Sellam J., Allanore Y., Batteux F., Job Deslandre C., Weill B., and Kahan A. Autoantibody induction in patients with refractory spondyloarthopathy treated with infliximab and methotrexate. Joint Bone Spine 72 (2005) 48-52
13. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
14. Clatworthy A.L., Illich P.A., Castro G.A., and Walters E.T. Role of periaxonal inflammation in the development of thermal hyperalgesia and guarding behavior in a rat model of neuropathic pain. Neurosci. Lett. 184 (1995) 5-8
15. Munoz-Fernandez M.A., and Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog. Neurobiol. 56 (1998) 307-340
16. Myers R.R., Wagner R., and Sorkin L.S. Hyperalgesic actions of cytokines on peripheral nerves. In: Watkins L.R., and Maier S.F. (Eds). Cytokines and pain. Basel, Switzerland (1999), Birkhauser Verlag, Boston 133-157
17. Wells M.R., Racis Jr. S.P., and Vaidya U. Changes in plasma cytokines associated with peripheral nerve injury. J. Neuroimmunol. 39 (1992) 261-268
18. Wagner R., Janjigian M., and Myers R.R. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 74 (1998) 35-42
19. Wagner R., and Myers R.R. Endoneurial injection of TNF-α[REMOVED INCLUDEPICTURE FIELD] produces neuropathic pain behaviors. Neuroreport 7 (1996) 2897-2901
20. Sommer C., Marziniak M., and Myers R.R. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 74 (1998) 83-91
21. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173 (1991) 699-703
22. Sommer C., Schmidt C., and George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp. Neurol. 151 (1998) 138-142
23. Liu B., Li H., Brull S.J., and Zhang J.M. Increased sensitivity of sensory neurons to tumor necrosis factor-alpha in rats with chronic compression of the lumbar ganglia. J. Neurophysiol. 88 (2002) 1393-1399
24. Schäfers M., Lee D.H., Brors D., Yaksh T.L., and Sorkin L.S. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J. Neurosci. 23 (2003) 3028-3038
25. Homma Y., Brull S.J., and Zhang J.M. A comparison of chronic pain behavior following local application of tumor necrosis factor-alpha to the normal, mechanically compressed lumbar ganglia in the rat. Pain 95 (2002) 239-246
26. Sommer C. Cytokines and neuropathic pain. In: Hansson P., Fields H., Hill R., and Marchettini P. (Eds). Neuropathic pain: pathophysiology and treatment (2001), IASP Press, Seattle, WA 37-62
27. Schäfers M., Geis C., Brors D., Yaksh T., and Sommer C. Anterograde transport of tumor necrosis factor-alpha in experimental mononeuropathy. J. Neurosci. 22 (2002) 236-245
28. Shamash S., Reichert F., and Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis-factor-alpha, interleukin-1 alpha, and interleukin-1 beta. J. Neurosci. 22 (2002) 3052-3060
29. Watkins L., Goehler L., Rekton J., Brewer M., and Maier S. Mechanisms of tumor necrosis factor-a (TNF-a) hyperalgesia. Brain Res. 692 (1995) 244-250
30. Sommer C., Lindenlaub T., Teuteberg P., Schäfers M., Hartung T., and Toyka K.V. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 913 (2001) 86-89
31. Lindholm D., Heumann R., Meyer M., and Thoenen H. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature 330 (1987) 658-659
32. Rotshenker S., Aamar S., and Barak V. Interleukin-1 activity in lesioned peripheral nerve. J. Neuroimmunol. 39 (1992) 75-80
33. Bolin L.M., Verity A.N., Silver J.E., Shooter E.M., and Abrams J.S. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J. Neurochem. 64 (1995) 850-858
34. Poole S., Cunha F.Q., Selkirk S., Lorenzetti B.B., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br. J. Pharmacol. 115 (1995) 684-688
35. Shubayev V.I., and Myers R.R. Endoneurial remodeling by TNFα and TNFα-releasing proteases. A spatial and temporal co-localization study in painful neuropathy. J. Peripher. Nerv. Syst. 7 (2002) 28-36
36. Ansel J.C., Brown J.R., Payan D.G., and Brown M.A. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J. Immunol. 150 (1993) 4478-4485
37. Redford E.J., Hall S.M., and Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumor necrosis factor. Brain 118 (1995) 869-878
38. Sorkin L.S., Xiao W.-H., Wagner R., and Myers R.R. Tumour necrosis factor-α[REMOVED INCLUDEPICTURE FIELD] induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81 (1997) 255-262
39. Sommer C., Schmidt C., George A., and Toyka K.V. A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci. Lett. 237 (1997) 45-48
40. Baldwin R.L., Stolowitz M.L., Hood I., and Wisnieski B.J. Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation. Proc. Natl. Acad. Sci. USA 93 (1996) 1021-1026
41. Kagan B.L., Baldwin R.L., Munoz D., and Wisnieski B.J. Formation of ion-permeable channels by tumor necrosis factor-alpha. Science 255 (1992) 1427-1430
42. Rand N., Reichert R., Floman Y., and Rotshenker S. Murine nucleus pulposus-derived cells secrete interleukins-1-beta, -6, and -10 and granulocyte-macrophage colony-stimulating factor in cell culture. Spine 22 (1997) 2598-2601
43. Murata Y., Onda A., Rydevik B., Takahashi K., and Olmarker K. Distribution and appearance of tumor necrosis factor-alpha in the dorsal root ganglion exposed to experimental disc herniation in rats. Spine 29 (2004) 2235-2241
44. Wagner R., and Myers R.R. Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 73 (1996) 625-629
45. Taskinen H.S., Olsson T., Bucht A., Khademi M., Svelander L., and Röyttä M. Peripheral nerve injury induces endoneurial expression of IFN-γ, IL-10 and TNF-α mRNA. J. Neuroimmunol. 102 (2000) 17-25
46. Igarashi T., Kikuchi S., Shubayev V., and Myers R.R. 2000 Volvo Award winner in basic science studies: Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats. Spine 25 (2000) 2975-2980
47. Aoki Y., Rydevik B., Kikuchi S., and Olmarker K. Local application of disc-related cytokines on spinal nerve roots. Spine 27 (2002) 1614-1617
48. George A., Marziniak M., Schafers M., Toyka K.V., and Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 88 (2000) 267-275
49. George A., Buehl A., and Sommer C. Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-alpha protein. Neurosci. Lett. 372 (2004) 215-219
50. Cunha F.Q., Poole S., Lorenzetti B.B., and Ferreira S.H. The pivotal role of tumor necrosis factor alpha in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 107 (1992) 660-664
51. Woolf C.J., Allchorne A., Safieh-Garabedian B., and Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumor necrosis factor alpha. Br. J. Pharmacol. 121 (1997) 417-424
52. Olmarker K., Storkson R., and Berge O.G. Pathogenesis of sciatic pain. A study of spontaneous behavior in rats exposed to experimental disc herniation. Spine 27 (2002) 1312-1317
53. Olmarker K., Nutu M., and Storkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-alpha inhibition. Spine 28 (2003) 1635-1642
54. Lindenlaub T., Teuteberg P., Hartung T., and Sommer C. Effects of neutralizing antibodies to TNF-alpha on pain-related behavior and nerve regeneration in mice with chronic constriction injury. Brain Res. 866 (2000) 15-22
55. Schäfers M., Brinkhoff J., Neukirchen S., Marziniak M., and Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci. Lett. 310 (2001) 113-116
56. Sommer C., Schäfers M., Marziniak M., and Toyka K.V. Etanercept reduces hyperalgesia in experimental painful neuropathy. J. Peripher. Nerv. Syst. 6 (2001) 67-72
57. Lamster I.B., Pullman J.R., Celenti R.S., and Grbic J.T. The effect of tetracycline fiber therapy on beta-glucuronidase and interleukin-1 beta in crevicular fluid. J. Clin. Periodontol. 23 (1996) 816-822
58. Steinmeyer J., Daufeldt S., and Taiwo Y.O. Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem. Pharmacol. 55 (1998) 93-100
59. Kloppenburg M., Verweij C.L., Miltenburg A.M., Verhoeven A.J., Daha M.R., Dijkmans B.A., et al. The influence of tetracyclines on T cell activation. Clin. Exp. Immunol. 102 (1995) 635-641
60. Amin A.R., Attur M.G., Thakker G.D., Patel P.D., Vyas P.R., Patel R.N., et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl. Acad. Sci. USA 93 (1996) 14014-14019
61. Chao C.C., Hu S., Ehrlich L., and Peterson P.K. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-d-aspartate receptors. Brain Behav. Immun. 9 (1995) 355-365
62. Hattori A., Iwasaki S., Murase K., Tsujimoto M., Sato M., Hayashi K., et al. Tumor necrosis factor is markedly synergistic with interleukin 1 and interferon-gamma in stimulating the production of nerve growth factor in fibroblasts. FEBS Lett. 340 (1994) 177-180
63. Olmarker K., and Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine 26 (2001) 863-869
64. Yabuki S., Igarashi T., and Kikuchi S. Application of nucleus pulposus to the nerve root simultaneously reduces blood flow in dorsal root ganglion and corresponding hindpaw in the rat. Spine 25 (2000) 1471-1476
65. Yabuki S., Kikuchi S., Olmarker K., and Myers R.R. Acute effects of nucleus pulposus on blood flow and endoneurial fluid pressure in rat dorsal root ganglia. Spine 23 (1998) 2517-2523
66. Mandi Y., Farkas G., and Ocsovszky I. Effects of pentoxifylline and pentaglobin on TNF and IL-6 production in septic patients. Acta Microbiol. Immunol. Hung. 42 (1995) 301-308
67. Yabuki S., Onda A., Kikuchi S., and Myers R.R. Prevention of compartment syndrome in dorsal root ganglia caused by exposure to nucleus pulposus. Spine 26 (2001) 870-875
68. Anzai H., Hamba M., Onda A., Konno S., and Kikuchi S. Epidural application of nucleus pulposus enhances nociresponses of rat dorsal horn neurons. Spine 27 (2002) E50-E55
69. Onda A., Hamba M., Yabuki S., and Kikuchi S. Exogenous tumor necrosis factor-alpha induces abnormal discharges in rat dorsal horn neurons. Spine 27 (2002) 1618-1624
70. Onda A., Yabuki S., and Kikuchi S. Effects of neutralizing antibodies to tumor necrosis factor-alpha on nucleus pulposus-induced abnormal nociresponses in rat dorsal horn neurons. Spine 28 (2003) 967-972
71. Onda A., Murata Y., Rydevik B., Larsson K., Kikuchi S., and Olmarker K. Immunoreactivity of brain-derived neurotrophic factor in rat dorsal root ganglion and spinal cord dorsal horn following exposure to herniated nucleus pulposus. Neurosci. Lett. 352 (2003) 49-52
72. Thompson S.W., Bennett D.L., Kerr B.J., Bradbury E.J., and McMahon S.B. Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc. Natl. Acad. Sci. USA 96 (1999) 7714-7718
73. Michael G.J., Averill S., Nitkunan A., Rattray M., Bennett D.L., Yan Q., et al. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci. 17 (1997) 8476-8490
74. Obata K., Tsujino H., Yamanaka H., Yi D., Fukuoka T., Hashimoto N., et al. Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation. Pain 99 (2002) 121-132
75. Onda A., Murata Y., Rydevik B., Larsson K., Kikuchi S., and Olmarker K. Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. Spine 29 (2004) 1857-1861
76. Murata Y., Onda A., Rydevik B., Takahashi K., and Olmarker K. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced histologic changes in the dorsal root ganglion. Spine 29 (2004) 2477-2484
77. Genevay S. Is disk-related sciatica a TNF-α-dependent inflammatory disease?. Jt. Bone Spine 72 (2005) 4-6
78. Karppinen J., Korhonen T., Malmivaara A., Paimela L., Kyllonen E., Lindgren K.A., et al. Tumor necrosis factor-alpha monoclonal antibody, Infliximab, used to manage severe sciatica. Spine 28 (2003) 750-753
79. Korhonen T., Karppinen J., Malmivaara A., Autio R., Niinimaki J., Paimela L., et al. Efficacy of Infliximab for disc herniation-induced sciatica. One-year follow-up. Spine 29 (2004) 2115-2119
80. Tobinick E.L. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin. Ther. 25 (2003) 1211-1218
81. Tobinick E.L., and Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss. Med. Wkly. 133 (2003) 170-177
82. Tobinick E.L., and Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr. Med. Res. Opin. 20 (2004) 1075-1085
83. Genevay S., Stingelin S., and Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann. Rheum. Dis. 63 (2004) 1120-1123
84. Atcheson S.G., and Dymeck T. Rapid resolution of chronic sciatica with intravenous infliximab after failed epidural steroid injections. Spine 29 (2004) E248-EE50
85. Shin K. Treatment of neck and back pain originating from herniated nucleus pulposus with tumor necrosis factor alpha inhibitor. Annual meeting of the International Society for the study of the lumbar spine (May 2004), Spine Week, Porto
86. Korhonen T., Karppinen J., Paimela L., Malmivaara A., Lindgren K.A., Järvinen S., et al. The efficacy of Infliximab for disc herniation-induced sciatica. A 3-month follow-up of First II, a randomised controlled trial. Annual meeting of the International Society for the study of the lumbar spine (May 2004), Spine Week, Porto
87. Miracle sciatica cure fails an early test. Back Lett. 19 (2004) 85-94
88. Cooper R.G., and Freemont A.J. TNF-α blockade for herniated intervertebral disc-induced sciatica: a way forward at last?. Rheumatol. 43 (2004) 119-121